143 related articles for article (PubMed ID: 35174529)
1. Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein.
Lafaie L; Hodin S; Saïb S; Bin V; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2022 Oct; 36(5):860-868. PubMed ID: 35174529
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein.
Margelidon-Cozzolino V; Hodin S; Jacqueroux E; Delézay O; Bertoletti L; Delavenne X
J Pharmacol Exp Ther; 2018 Jun; 365(3):519-525. PubMed ID: 29572341
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
Zielinski GD; Teichert M; Klok FA; Rosendaal FR; Huisman MV; Cannegieter SC; Lijfering WM
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1371-1378. PubMed ID: 30443944
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
8. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users.
Kawano Y; Nagata M; Nakamura S; Akagi Y; Suzuki T; Tsukada E; Hoshiko M; Kujirai A; Nakamatsu S; Nishikawa T; Enomoto A; Negishi K; Shimada S; Aoyama T; Mano Y
Biol Pharm Bull; 2021; 44(5):611-619. PubMed ID: 33952817
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
11. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.
Hanigan S; Das J; Pogue K; Barnes GD; Dorsch MP
J Thromb Thrombolysis; 2020 May; 49(4):636-643. PubMed ID: 31925665
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.
Hodin S; Basset T; Jacqueroux E; Delezay O; Clotagatide A; Perek N; Mismetti P; Delavenne X
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):183-191. PubMed ID: 28895074
[TBL] [Abstract][Full Text] [Related]
14. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
[TBL] [Abstract][Full Text] [Related]
15. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
Hedvat J; Howlett C; McCloskey J; Patel R
J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
[TBL] [Abstract][Full Text] [Related]
19. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.
Highcock AJ; As-Sultany M; Finley R; Donnachie NJ
J Arthroplasty; 2020 Nov; 35(11):3093-3098. PubMed ID: 32674939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
